Predictive Oncology Inc Financials

POAI

FY2025 annual

Revenue $125K +47.7% YoY

Net Income -$233.1M -1740.6% YoY

EPS (Diluted) Not reported for FY2025

Free Cash Flow -$9.9M +2.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 15, 2026 Currency USD FYE December

Predictive Oncology Inc (POAI) reported $125K in revenue for fiscal year 2025, up 47.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI POAI FY2025 2026-08-30

A thin-revenue balance sheet is being reshaped while operating losses materially dwarf the sales base.

In FY2025, the reported-loss-to-cash gap is unusually wide: operating loss was -$180.9M while operating cash flow was -$9.9M. Against revenue of $125K, that mismatch indicates earnings were heavily affected by items that did not use cash in the same period, making cash flow a more informative gauge of current operating burden.

The balance sheet moved from -$203K of equity and a 0.6x current ratio in FY2024 to $47.7M of equity and a 10.0x current ratio in FY2025, a structural reset that cannot be explained by the small change in sales alone. The reported liquidity comparison equaled 13.1 months of latest annual operating outflow, describing funding relative to cash use rather than commercial traction.

Gross margin rebounded from 7.7% in FY2024 to 42.0% in FY2025. Yet FY2025 revenue was $125K while SG&A was $25.9M, so the gross-profit pool remains too small to absorb the cost base.

Financial Health Signals

Financial health score not available

Predictive Oncology Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-20.10

Predictive Oncology Inc scores -20.10, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($10.9M) relative to total liabilities ($5.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Predictive Oncology Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Predictive Oncology Inc reported a net loss of $233.1M while operations used $9.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$125K

YoY+47.7%

5Y CAGR-36.9%

10Y CAGR-15.2%

Predictive Oncology Inc generated $125K in revenue in fiscal year 2025. This represents an increase of 47.7% from the prior year.

EBITDA

-$180.8M

YoY-1677.4%

Predictive Oncology Inc's EBITDA was -$180.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1677.4% from the prior year.

Net Income

-$233.1M

YoY-1740.6%

Predictive Oncology Inc reported -$233.1M in net income in fiscal year 2025. This represents a decrease of 1740.6% from the prior year.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$9.9M

YoY+2.3%

Predictive Oncology Inc recorded an outflow of $9.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 2.3% from the prior year.

Cash & Debt

$10.8M

YoY+1663.7%

5Y CAGR+73.9%

10Y CAGR+8.3%

Predictive Oncology Inc held $10.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

Predictive Oncology Inc had 4M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

42.0%

YoY+34.3pp

5Y CAGR-22.3pp

10Y CAGR-11.5pp

Predictive Oncology Inc's gross margin was 42.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 34.3 percentage points from the prior year.

Return on Equity

-488.5%

Predictive Oncology Inc's ROE was -488.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

Capital Expenditures

YoY-100.0%

Predictive Oncology Inc reported no capital expenditure in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

R&D Spending

Not reported for fiscal year 2025.

Share Buybacks

Not reported for fiscal year 2025.

POAI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

POAI quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$50K	$125K+47.7%	$85K-82.8%	$493K-67.3%	$1.5M+6.0%	$1.4M+13.4%	$1.3M-11.3%	$1.4M0.0%	$1.4M+115.6%	$655K+43.4%	$456K-30.2%	$654K-31.2%	$952K+103.3%	$468K+148.0%	$189K+95.3%	$97K
Cost of Revenue	$1.1M	$73K-7.2%	$78K-59.9%	$195K-61.4%	$505K+3.7%	$487K+8.9%	$447K-15.9%	$532K+27.9%	$416K+180.8%	$148K-18.5%	$182K-40.3%	$304K-21.1%	$385K+103.1%	$190K+47.6%	$129K+129.2%	$56K
Gross Profit	-$3.4M	$53K+706.8%	$7K-97.8%	$297K-70.3%	$1.0M+7.1%	$934K+16.0%	$805K-8.5%	$880K-11.7%	$996K+96.5%	$507K+84.4%	$275K-21.5%	$350K-38.1%	$566K+103.4%	$278K+362.2%	$60K+48.5%	$41K
R&D Expenses	N/A	N/A	$2.2M+2184.5%	$98K-69.4%	$320K+1.4%	$316K-15.3%	$373K-11.9%	$423K-19.6%	$526K+82.1%	$289K-28.8%	$406K+55.6%	$261K-33.8%	$394K+67.7%	$235K+1466.7%	$15K	$0
SG&A Expenses	$27.0M	$25.9M+258.3%	$7.2M-8.0%	$7.9M-29.2%	$11.1M+1.6%	$10.9M+5.6%	$10.4M+5.8%	$9.8M+111.4%	$4.6M+14.2%	$4.1M-21.7%	$5.2M+52.2%	$3.4M	N/A	N/A	N/A	N/A
Operating Income	-$186.4M	-$180.9M-1655.8%	-$10.3M+7.6%	-$11.1M+57.2%	-$26.0M-27.4%	-$20.4M+19.4%	-$25.4M-12.0%	-$22.6M-188.1%	-$7.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3-100.0%	$391K+3.5%	$378K-40.7%	$637K+145.4%	$259K+12.6%	$230K
Income Tax	N/A	$0	$0	$0	$0+100.0%	-$662K	$0	$0	N/A	$0	$0	$0	N/A	N/A	N/A	N/A
Net Income	N/A	-$233.1M-1740.6%	-$12.7M+9.4%	-$14.0M+45.7%	-$25.7M-30.9%	-$19.7M+24.1%	-$25.9M-33.5%	-$19.4M-92.2%	-$10.1M-68.0%	-$6.0M+8.0%	-$6.5M-36.2%	-$4.8M	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$35K+307.1%	$9K+139.7%	$4K+34.9%	$3K-97.6%	$110K+1154.7%	$9K+125.0%	$4K-94.2%	$67K
Cost of Revenue	$3.5M+247.5%	-$2.4M-28239.2%	$8K-54.1%	$18K-99.2%	$2.4M+7679.3%	$31K+175.7%	$11K-19.3%	$14K
Gross Profit	-$3.4M-44406.4%	$8K+263.5%	-$5K+69.5%	-$16K+99.3%	-$2.3M-10283.9%	-$22K-203.0%	-$7K-113.6%	$53K
SG&A Expenses	$2.9M-85.2%	$19.6M+650.4%	$2.6M+39.3%	$1.9M+2.6%	$1.8M+18.7%	$1.5M-0.4%	$1.5M-15.3%	$1.8M
Operating Income	-$7.7M+95.5%	-$172.7M-5165.1%	-$3.3M-23.3%	-$2.7M-16.3%	-$2.3M-9.1%	-$2.1M+2.9%	-$2.2M+12.3%	-$2.5M
Net Income	-$7.7M	N/A	N/A	-$2.1M+15.2%	-$2.4M-12.6%	-$2.2M+29.9%	-$3.1M+2.7%	-$3.2M

Not reported in any period shown, so not listed: R&D Expenses, Interest Expense, Income Tax, EPS (Diluted).

POAI Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

POAI quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$52.9M+963.6%	$5.0M-65.5%	$14.4M-44.0%	$25.7M-41.2%	$43.8M+235.1%	$13.1M-41.6%	$22.4M+503.3%	$3.7M+2.3%	$3.6M+29.1%	$2.8M-50.2%	$5.6M+525.1%	$901K+51.8%	$593K+60.6%	$370K-17.2%	$446K
Current Assets	$42.8M+1821.5%	$2.2M-77.9%	$10.1M-56.9%	$23.4M-20.7%	$29.5M+1845.4%	$1.5M+89.7%	$798K-45.0%	$1.5M-38.8%	$2.4M-9.1%	$2.6M-51.7%	$5.4M+755.0%	$631K+65.3%	$382K+69.4%	$225K-25.1%	$301K
Cash & Equivalents	$10.8M+1663.7%	$612K-92.7%	$8.4M-62.1%	$22.1M-21.7%	$28.2M+4057.6%	$678K+349.7%	$151K-7.0%	$162K-78.8%	$766K-56.6%	$1.8M-63.7%	$4.9M+29540.1%	$16K-83.9%	$102K+676.0%	$13K-89.3%	$123K
Inventory	N/A	$46K-24.6%	$61K-85.9%	$430K+11.0%	$388K+33.9%	$290K+52.3%	$190K-21.1%	$241K-9.0%	$265K-2.6%	$272K+17.5%	$232K-36.9%	$367K+200.7%	$122K-15.9%	$145K+48.8%	$98K
Accounts Receivable	$32K-6.0%	$34K-57.3%	$80K-75.9%	$331K-6.5%	$354K+37.9%	$257K-13.5%	$297K+27.7%	$233K+69.2%	$137K+253.3%	$39K+1.7%	$38K-33.5%	$58K-40.8%	$97K+144.9%	$40K-21.0%	$50K
Goodwill	N/A	N/A	N/A	$0-100.0%	$6.9M+143.7%	$2.8M-82.1%	$15.7M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.2M-0.1%	$5.2M-15.8%	$6.1M+54.8%	$4.0M+13.2%	$3.5M-66.3%	$10.4M-6.5%	$11.1M+204.9%	$3.7M+292.1%	$932K-50.5%	$1.9M+24.0%	$1.5M-76.3%	$6.4M+68.3%	$3.8M+3.8%	$3.7M+16.6%	$3.1M
Current Liabilities	$4.3M+18.7%	$3.6M-9.1%	$4.0M+1.8%	$3.9M+19.8%	$3.2M-65.3%	$9.3M-14.1%	$10.9M+197.5%	$3.7M+292.1%	$932K-40.8%	$1.6M+3.6%	$1.5M-75.5%	$6.2M+78.8%	$3.5M+1.6%	$3.4M+45.1%	$2.4M
Long-Term Debt	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$89K-85.8%	$630K
Total Equity	$47.7M+23651.1%	-$203K-102.4%	$8.3M-62.0%	$21.8M-45.9%	$40.3M+1423.7%	$2.6M-76.5%	$11.2M+20904.1%	$53K-98.0%	$2.7M+191.4%	$924K-77.5%	$4.1M+174.6%	-$5.5M-71.4%	-$3.2M+2.6%	-$3.3M-22.2%	-$2.7M
Retained Earnings	-$413.5M-129.2%	-$180.4M-7.5%	-$167.8M-9.1%	-$153.8M-20.1%	-$128.0M-18.1%	-$108.4M-31.4%	-$82.5M-30.7%	-$63.1M-19.0%	-$53.0M-12.8%	-$47.0M-16.1%	-$40.5M-13.6%	-$35.6M	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$45.2M-14.5%	$52.9M+1585.8%	$3.1M-8.7%	$3.4M-41.5%	$5.9M+18.0%	$5.0M-33.7%	$7.5M-29.2%	$10.6M
Current Assets	$37.6M-12.1%	$42.8M+3774.3%	$1.1M-9.8%	$1.2M-64.9%	$3.5M+56.6%	$2.2M-51.3%	$4.6M-33.7%	$6.9M
Cash & Equivalents	$6.9M-35.8%	$10.8M+5839.9%	$182K-64.1%	$506K-83.6%	$3.1M+404.7%	$612K-80.1%	$3.1M-42.3%	$5.3M
Inventory	N/A	N/A	$38K-11.0%	$43K-6.7%	$46K0.0%	$46K-90.9%	$504K-11.2%	$568K
Accounts Receivable	$659K+1952.7%	$32K+23.5%	$26K+13.3%	$23K-61.6%	$60K+75.2%	$34K-92.6%	$464K+19.8%	$387K
Total Liabilities	$5.0M-4.2%	$5.2M-93.6%	$80.6M+1483.2%	$5.1M-15.4%	$6.0M+16.2%	$5.2M-6.4%	$5.5M-14.8%	$6.5M
Current Liabilities	$4.2M-0.9%	$4.3M-94.6%	$79.5M+1967.1%	$3.8M-16.6%	$4.6M+28.3%	$3.6M-5.9%	$3.8M-17.4%	$4.6M
Total Equity	$40.3M-15.6%	$47.7M+161.6%	-$77.4M-4583.0%	-$1.7M-1034.1%	-$146K+28.0%	-$203K-110.3%	$2.0M-52.0%	$4.1M
Retained Earnings	-$421.2M-1.9%	-$413.5M-57.5%	-$262.6M-42.0%	-$184.9M-1.1%	-$182.9M-1.4%	-$180.4M-1.2%	-$178.3M-1.8%	-$175.2M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

POAI Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

POAI quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$12.6M	-$9.9M+2.2%	-$10.1M+23.4%	-$13.2M-6.6%	-$12.4M-1.3%	-$12.2M+0.4%	-$12.3M-40.4%	-$8.7M-65.1%	-$5.3M-18.6%	-$4.5M-1.8%	-$4.4M+41.5%	-$7.5M-122.1%	-$3.4M	N/A	-$1.2M+33.5%	-$1.8M
Capital Expenditures	$21K	$0-100.0%	$10K+1.5%	$9K-97.8%	$420K-53.9%	$910K+205.1%	$298K+4967.6%	$6K-96.7%	$178K+294.1%	$45K+37.6%	$33K+0.9%	$32K-68.0%	$101K-37.7%	$163K	$0	$0
Free Cash Flow	-$12.7M	-$9.9M+2.3%	-$10.1M+23.4%	-$13.2M-3.2%	-$12.8M+2.5%	-$13.1M-4.5%	-$12.6M-43.7%	-$8.7M-59.9%	-$5.5M-21.3%	-$4.5M-2.1%	-$4.4M+41.3%	-$7.5M-116.5%	-$3.5M	N/A	-$1.2M+33.5%	-$1.8M
Investing Cash Flow	N/A	N/A	N/A	-$302K+36.4%	-$476K+95.5%	-$10.6M-6234.5%	-$167K+72.0%	-$599K+46.1%	-$1.1M+32.8%	-$1.7M-290.9%	-$423K	N/A	N/A	N/A	$0	$0
Financing Cash Flow	N/A	N/A	N/A	$149K-97.8%	$6.7M-86.7%	$50.3M+288.7%	$13.0M+39.0%	$9.3M+60.8%	$5.8M+13.3%	$5.1M+198.7%	$1.7M	N/A	N/A	N/A	$1.1M-43.3%	$1.9M
Share Buybacks	N/A	N/A	$0-100.0%	$2K-94.5%	$28K+139.9%	$12K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.7M+5.0%	-$3.9M-138.3%	-$1.7M+49.8%	-$3.3M-234.2%	-$986K+52.0%	-$2.1M+19.3%	-$2.5M-21.9%	-$2.1M
Capital Expenditures	$21K	$0	$0	$0	$0-100.0%	$6K	$0	$0
Free Cash Flow	-$3.8M+4.4%	-$3.9M-138.3%	-$1.7M+49.8%	-$3.3M-234.2%	-$986K+52.1%	-$2.1M+19.1%	-$2.5M-21.9%	-$2.1M
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$6K
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3.4M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

POAI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

POAI quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	42.0%+34.3pp	7.7%-52.7pp	60.4%-6.1pp	66.5%+0.7pp	65.7%+1.4pp	64.3%+2.0pp	62.3%-8.2pp	70.5%-6.8pp	77.4%+17.2pp	60.2%+6.7pp	53.5%-6.0pp	59.5%0.0pp	59.5%+27.6pp	31.9%-10.1pp	42.0%
Operating Margin	-144404.5%	-12149.1%	-2263.4%	-1729.3%	-1438.0%	-2025.1%	-1604.2%	-556.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-186053.5%	-14932.3%	-2838.8%	-1709.6%	-1383.6%	-2067.0%	-1373.7%	-714.5%	-916.7%	-1429.6%	-732.1%	N/A	N/A	N/A	N/A
Return on Equity	-488.5%	N/A	-169.1%-50.8pp	-118.3%-69.4pp	-48.8%+930.6pp	-979.5%-806.8pp	-172.7%+18690.5pp	-18863.1%-18640.1pp	-223.0%+483.5pp	-706.5%-590.0pp	-116.5%	N/A	N/A	N/A	N/A
Return on Assets	-440.7%-186.0pp	-254.7%-157.7pp	-97.0%+3.0pp	-100.0%-55.1pp	-44.9%+153.3pp	-198.2%-111.5pp	-86.7%+185.3pp	-271.9%-106.3pp	-165.6%+66.8pp	-232.4%-147.4pp	-85.0%	N/A	N/A	N/A	N/A
Current Ratio	10.02+9.4x	0.62-1.9x	2.55-3.5x	6.02-3.1x	9.09+8.9x	0.16+0.1x	0.07-0.3x	0.40-2.1x	2.54+0.9x	1.66-1.9x	3.55+3.5x	0.100.0x	0.110.0x	0.07-0.1x	0.13
Debt-to-Equity	0.11	N/A	0.74+0.6x	0.18+0.2x	0.00-3.9x	3.94+2.9x	0.99-67.4x	68.36+68.0x	0.35-1.7x	2.04+1.7x	0.37	N/A	N/A	N/A	N/A
FCF Margin	-7882.9%	-11923.5%	-2679.4%	-849.6%	-923.5%	-1002.7%	-619.0%	-387.2%	-687.9%	-967.0%	-1149.2%	-365.0%	N/A	-627.3%	-1843.6%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	-9720.5%	89.3%	-131.0%	-579.4%	-2073.3%	-250.5%	-186.1%	79.4%
Operating Margin	-21887.5%	-1990880.1%	-90654.1%	-99174.8%	-2073.3%	-23848.9%	-55296.8%	-3664.6%
Net Margin	-21831.6%	N/A	N/A	-77198.4%	-2214.5%	-24676.9%	-79208.9%	-4730.1%
Return on Equity	-19.1%	N/A	N/A	N/A	N/A	N/A	-157.3%-79.6pp	-77.7%
Return on Assets	-17.1%	N/A	N/A	-60.3%-18.6pp	-41.6%+2.0pp	-43.6%-2.4pp	-41.3%-11.2pp	-30.0%
Current Ratio	8.89-1.1x	10.02+10.0x	0.01-0.3x	0.32-0.4x	0.76+0.1x	0.62-0.6x	1.20-0.3x	1.49
Debt-to-Equity	0.120.0x	0.11	N/A	N/A	N/A	N/A	2.81+1.2x	1.59
FCF Margin	-10669.3%	-45440.9%	-45712.1%	-122848.3%	-893.7%	-23429.1%	-65152.8%	-3104.8%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

BULLFROG AI HLDGS INC BFRG

$10.0M

VSee Health, Inc. VSEE

$4.7M

Healthcare Triangle Inc HCTI

$12.4M

Dariohealth Corp DRIO

$66.3M

Streamline Health Solutions In STRM

$23.2M

Where Predictive Oncology Inc Ranks

Frequently Asked Questions

What is Predictive Oncology Inc's annual revenue?

Predictive Oncology Inc (POAI) reported $125K in total revenue for fiscal year 2025. This represents a 47.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Predictive Oncology Inc's revenue growing?

Predictive Oncology Inc (POAI) revenue grew by 47.7% year-over-year, from $85K to $125K in fiscal year 2025.

Is Predictive Oncology Inc profitable?

No, Predictive Oncology Inc (POAI) reported a net income of -$233.1M in fiscal year 2025.

What is Predictive Oncology Inc's EBITDA?

Predictive Oncology Inc (POAI) had EBITDA of -$180.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Predictive Oncology Inc's gross margin?

Predictive Oncology Inc (POAI) had a gross margin of 42.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Predictive Oncology Inc's return on equity (ROE)?

Predictive Oncology Inc (POAI) has a return on equity of -488.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Predictive Oncology Inc's free cash flow?

Predictive Oncology Inc (POAI) recorded an outflow of $9.9M in free cash flow during fiscal year 2025. This represents a 2.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Predictive Oncology Inc's operating cash flow?

Predictive Oncology Inc (POAI) recorded an outflow of $9.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Predictive Oncology Inc's total assets?

Predictive Oncology Inc (POAI) had $52.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Predictive Oncology Inc's capital expenditures?

Predictive Oncology Inc (POAI) reported no capital expenditure during fiscal year 2025.

How many shares does Predictive Oncology Inc have outstanding?

Predictive Oncology Inc (POAI) had 4M shares outstanding as of fiscal year 2025.

What is Predictive Oncology Inc's current ratio?

Predictive Oncology Inc (POAI) had a current ratio of 10.02 as of fiscal year 2025, which is generally considered healthy.

What is Predictive Oncology Inc's debt-to-equity ratio?

Predictive Oncology Inc (POAI) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Predictive Oncology Inc's return on assets (ROA)?

Predictive Oncology Inc (POAI) had a return on assets of -440.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Predictive Oncology Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Predictive Oncology Inc (POAI) held $10.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.9M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Predictive Oncology Inc's Altman Z-Score?

Predictive Oncology Inc (POAI) has an Altman Z-Score of -20.10, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Predictive Oncology Inc's Piotroski F-Score?

Predictive Oncology Inc (POAI) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Predictive Oncology Inc's earnings high quality?

Predictive Oncology Inc (POAI) reported a net loss of $233.1M while operations used $9.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.